fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Mutual Funds » Nippon India PHARMA Fund

Nippon India PHARMA Fund - G

NAV  ₹426.398 ↓ -4.99  (-1.16 %) as on 12 Apr 24

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 20.8% since its launch.  Ranked 35 in Sectoral category.  Return for 2023 was 39.2% , 2022 was -9.9% and 2021 was 23.9% .

Below is the key information for Nippon India Pharma Fund

NAV as on 12 Apr 24₹426.398 ↓ -4.99  (-1.16 %)
Net Assets (AUM) as on 29 Feb 2024 ₹7,132 Cr.
Launch Date5 Jun 2004
CategoryEquity - Sectoral
Rating
TypeOpen Ended Fund
RiskHigh
AMCNippon Life Asset Management Ltd.
Alpha Ratio1.41
Expense Ratio1.97 %
Sharpe Ratio3.091
Information Ratio0.54
BenchmarkNot Available
Min Investment ₹5,000
Min SIP Investment ₹100
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 12 Apr 24

DurationReturns
1 Month 0.5%
3 Month 4.9%
6 Month 22%
1 Year 51.6%
3 Year 17.2%
5 Year 22.8%
10 Year
15 Year
Since launch 20.8%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

YearReturns
2023 39.2%
2022 -9.9%
2021 23.9%
2020 66.4%
2019 1.7%
2018 3.6%
2017 7.6%
2016 -10.6%
2015 19.4%

Growth of 10k Over Years

DateValue
31 Mar 19₹10,000
31 Mar 20₹9,449
31 Mar 21₹16,485
31 Mar 22₹19,119
31 Mar 23₹17,831
31 Mar 24₹28,260
Nippon India PHARMA Fund Growth 10k Chart

Asset Allocation

Asset ClassValue
Cash2.05%
Equity97.95%
Nippon India PHARMA Fund Asset Allocation

Sector Allocation

SectorValue
Health Care97.95%
Nippon India PHARMA Fund Equity Allocation

Top Securities Holdings / Portfolio

Holdings/Securities

NameGlobal IndustryHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
Drug Manufacturers - Specialty & Generic15%₹1,035 Cr6,556,349
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257
Drug Manufacturers - Specialty & Generic8%₹600 Cr3,703,676
↓ -100,000
Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 500087
Drug Manufacturers - General6%₹459 Cr3,100,000
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP
Medical Care Facilities6%₹396 Cr648,795
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY
Drug Manufacturers - Specialty & Generic5%₹353 Cr550,030
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
Drug Manufacturers - Specialty & Generic4%₹314 Cr900,808
↑ 50,000
Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND
Drug Manufacturers - General4%₹300 Cr1,700,000
Zydus Lifesciences Ltd (Healthcare)
Equity, Since 31 Jan 18 | 532321
Drug Manufacturers - Specialty & Generic4%₹283 Cr3,000,835
Abbott India Ltd (Healthcare)
Equity, Since 31 May 11 | ABBOTINDIA
Drug Manufacturers - General3%₹246 Cr86,390
↑ 10,000
J.B. Chemicals & Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Jan 22 | JBCHEPHARM
Drug Manufacturers - Specialty & Generic3%₹232 Cr1,486,868
1 - 10 of 35
Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Fund Managers

NameSinceTenure
Sailesh Raj Bhan1 Apr 0519.01 Yr.
Kinjal Desai25 May 185.86 Yr.

Custodians

CompanyAddress
Deutsche Bank AGDeutsche Bank AG,Kodak House, 22, D.N. Road,

Registrar & Transfer Agent

KFin Technologies Ltd
AddressKFin Technologies Pvt. Ltd,,1D/D Extension 2, Valmiki Chowk,,Gandhi Nagar,
FAX91-40-23311968
Emailmailmanager@karvy.com

Administrator Companies

CompanyAddress
Nippon India Mutual Fund9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

CompanyAddress
Haribhakti & Co. Chartered Accountants42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and PlanNAV6 Month1 Year3 Year5 Year
Nippon India Pharma Fund
Normal Dividend, Payout
₹108.562
↓ -1.27
21.13 %50.47 %18.59 %25.26 %
Nippon India Pharma Fund
Normal Dividend, Reinvestment
₹108.562
↓ -1.27
21.13 %50.47 %18.59 %25.26 %
Nippon India Pharma Fund
Growth
₹426.398
↓ -4.99
22.03 %51.59 %17.21 %22.75 %
Data as on 12 Apr 24

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.